PharmaCyte Biotech, Inc. reported its financial results for the three and six months ended October 31, 2025, revealing a net loss of $7.4 million for the quarter and $15.8 million for the half-year, compared to a loss of $1.5 million and a profit of $22 million, respectively, in the same periods of the previous year. The company did not generate any revenue during these periods, maintaining a consistent trend from the previous year. Operating expenses increased to $1.4 million for the quarter, up from $1.1 million, primarily due to higher research and development costs, which rose to $141,085 from $97,470, reflecting ongoing efforts in cancer treatment research.
The company’s total assets as of October 31, 2025, stood at approximately $56 million, a slight increase from $55.2 million at the end of April 2025. Current assets also saw a modest rise, reaching $23 million, driven by an increase in cash and cash equivalents, which totaled $15.4 million, compared to $15.2 million at the previous reporting date. However, total liabilities surged to $19.4 million from $3.3 million, largely due to a significant increase in warrant liabilities, which rose to $16.2 million from $338,000.
Strategically, PharmaCyte Biotech has been focusing on its proprietary Cell-in-a-Box® technology, aimed at developing therapies for pancreatic cancer. The company has been in discussions with the FDA to lift a clinical hold on its Investigational New Drug Application (IND) for a planned trial in locally advanced pancreatic cancer. The FDA has requested additional studies and data, which the company is currently addressing. In August 2025, PharmaCyte entered into a securities purchase agreement, raising $7 million through the sale of Series C convertible preferred stock and warrants, which is expected to support its operational needs.
Operationally, the company has been reviewing its relationship with SG Austria, which holds critical patents and know-how related to its technology. This review has led to a temporary curtailment of spending on development programs until a new framework is established. As of October 31, 2025, PharmaCyte had 10,134,160 shares of common stock outstanding, with a par value of $0.0001 per share. The company anticipates that its current cash reserves will be sufficient to meet its operational requirements for at least the next twelve months, although it acknowledges the need for additional capital to complete its clinical trials.
Looking ahead, PharmaCyte Biotech faces significant challenges, including the need to regain compliance with Nasdaq's minimum bid price requirement, as it received a notice of non-compliance in December 2025. The company has a 180-day grace period to address this issue. Additionally, it must navigate the complexities of regulatory approvals and the ongoing development of its cancer therapies, which are subject to market conditions and the success of its clinical trials.
About PharmaCyte Biotech, Inc.
PharmaCyte Biotech develops cellular therapies for cancer using proprietary live cell encapsulation technology, Cell-in-a-Box. Its focus includes treatments for pancreatic tumors, leveraging genetically engineered cells to activate prodrugs at tumor sites. The company aims to address unmet medical needs with targeted, minimally immunogenic therapies, operating within the biotech and cancer treatment markets, with a strong emphasis on regulatory compliance and intellectual property protection.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.